Stryker/$SYK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stryker
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
Ticker
$SYK
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
53,000
ISIN
US8636671013
Website
Stryker Metrics
BasicAdvanced
$149B
52.76
$7.40
0.94
$3.28
0.86%
Price and volume
Market cap
$149B
Beta
0.94
52-week high
$406.19
52-week low
$314.93
Average daily volume
1.2M
Dividend rate
$3.28
Financial strength
Current ratio
1.642
Quick ratio
0.803
Long term debt to equity
70.698
Total debt to equity
82.924
Dividend payout ratio (TTM)
43.20%
Interest coverage (TTM)
12.92%
Profitability
EBITDA (TTM)
6,177
Gross margin (TTM)
64.70%
Net profit margin (TTM)
12.31%
Operating margin (TTM)
22.03%
Effective tax rate (TTM)
14.22%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
7.49%
Return on equity (TTM)
14.26%
Valuation
Price to earnings (TTM)
52.757
Price to revenue (TTM)
6.412
Price to book
7.13
Price to tangible book (TTM)
-34.77
Price to free cash flow (TTM)
41.618
Free cash flow yield (TTM)
2.40%
Free cash flow per share (TTM)
938.04%
Dividend yield (TTM)
0.84%
Forward dividend yield
0.86%
Growth
Revenue change (TTM)
10.76%
Earnings per share change (TTM)
-15.51%
3-year revenue growth (CAGR)
10.03%
10-year revenue growth (CAGR)
9.07%
3-year earnings per share growth (CAGR)
12.06%
10-year earnings per share growth (CAGR)
15.58%
3-year dividend per share growth (CAGR)
7.37%
10-year dividend per share growth (CAGR)
9.70%
What the Analysts think about Stryker
Analyst ratings (Buy, Hold, Sell) for Stryker stock.
Bulls say / Bears say
Stryker's acquisition of Inari Medical expands its portfolio into the high-growth peripheral vascular segment, potentially driving future revenue growth. (stockinvest.us)
Analysts have raised Stryker's price targets following strong earnings, with Jefferies increasing its target to $465, indicating confidence in the company's performance. (tradingview.com)
Stryker's Mako robotic-assisted surgery systems are experiencing solid demand, with record installations in the U.S. and worldwide, contributing to a 10% year-over-year sales growth in 2024. (finviz.com)
Stryker's premium valuation raises concerns about its ability to sustain growth and justify its high stock price. (investing.com)
The divestiture of Stryker's U.S. spinal implants business may lead to short-term revenue declines and market share loss in the spine segment. (financecharts.com)
Stryker's stock dipped after announcing the sale of its U.S. spinal business, despite a quarterly earnings beat, indicating potential investor concerns over the strategic move. (financecharts.com)
Data summarised monthly by Lightyear AI. Last updated on 22 Jun 2025.
Stryker Financial Performance
Revenues and expenses
Stryker Earnings Performance
Company profitability
Stryker News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun30
Stryker
Dividend·Ex-dividend
Jul31
Stryker
Dividend·Payment
$0.84Per share
FAQs
What’s the current market cap for Stryker stock?
Stryker (SYK) has a market cap of $149B as of June 27, 2025.
What is the P/E ratio for Stryker stock?
The price to earnings (P/E) ratio for Stryker (SYK) stock is 52.76 as of June 27, 2025.
Does Stryker stock pay dividends?
Yes, the Stryker (SYK) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $3.28 and the yield is 0.86%. Stryker has a payout ratio of 43.2% on a trailing twelve-month basis.
When is the next Stryker dividend payment date?
The next Stryker (SYK) dividend payment is scheduled for July 31, 2025.
What is the beta indicator for Stryker?
Stryker (SYK) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.